Sanofi (ENXTPA:SAN) received FDA approval for Dupixent as the first and only treatment for allergic fungal rhinosinusitis, expanding its use into a new indication. The company also appointed Belén ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis in both adults and children. The FDA also accepted garetosmab for ...
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...
Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results